Medicus Pharma Eyes SPAC Deal for SkinJect
A non-binding letter of intent would take Medicus Pharma's SkinJect subsidiary public through a special purpose acquisition company.
Updated on Nov. 4, 2026 in Healthcare
Medicus Pharma's wholly owned subsidiary SkinJect Inc. signed a non-binding letter of intent with an undisclosed special purpose acquisition company for a proposed business combination. The deal values SkinJect at $135 million before money and would create a separately listed company dedicated to the asset.
Why it matters
The transaction is intended to unlock the value of SkinJect as a clinical-stage asset and give it an independent public-market platform with access to capital. Medicus seeks to retain majority economic and voting ownership of the combined company.
The proposed deal values SkinJect at $135 million before money, with the special purpose acquisition company acquiring 100% of SkinJect in exchange for newly issued common shares of the combined company. Final ownership percentages remain subject to definitive agreement terms still under negotiation.
The players
Medicus Pharma
Medicus Pharma is a clinical-stage pharmaceutical company that owns the SkinJect subsidiary and is pursuing its development.
U.S. Food and Drug Administration
The U.S. Food and Drug Administration is the federal agency that regulates drugs and issued the Study May Proceed letter for SKNJCT-005.
The details
SkinJect is an investigational dissolvable microneedle-array patch designed to deliver doxorubicin into basal cell carcinoma lesions. Medicus has focused future internally sponsored development of SkinJect on Gorlin syndrome, and the FDA issued a Study May Proceed letter authorizing the start of the SKNJCT-005 study.
Timeline
November 4, 2026: Medicus announced the non-binding SPAC letter of intent.
First half of 2027: The company anticipates closing the business combination.
Market Landscape
The proposal follows the pattern of carving a single clinical-stage asset into its own listed vehicle through a special purpose acquisition company, a route biotechnology firms have used to access public-market capital. It positions SkinJect's dermatology-focused microneedle program as a standalone investment separate from Medicus's broader portfolio.
For shareholders of Medicus Pharma, the transaction would convert their stake in SkinJect into shares of a separately listed company. Investors gain exposure to a single clinical-stage asset rather than a diversified pipeline, which carries the risks of early-stage drug development.
The takeaway
Investors evaluating SPAC-listed clinical-stage companies should watch for the definitive agreement, which will set final ownership and capitalization terms. Until then, the $135 million valuation and the 2027 closing timeline are the key reference points.
What happens next
The companies expect to close the business combination in the first half of 2027, with concurrent equity financing supporting the SKNJCT-005 study and preparation of a potential New Drug Application.
Further reading
Explore more Healthcare coverage for context on biotechnology financing and drug development.
